GEMA Biotech is an Argentine biotechnology company specializing in the development, production, and commercialization of recombinant protein medicines, along with a line of special treatments. Founded in 1998, it initially focused on basic research in molecular biology before refocusing on biotech drug development in 2005 as a member of AMEGA Biotech, and is a Megalabs company. It operates state-of-the-art production plants in Santa Fe and Buenos Aires, with an integrated value chain from cell engineering to finished product under GMP standards. The company was a regional pioneer, launching the first biosimilar of Etanercept in the region in 2019, and maintains a global presence across the Americas, Europe, Asia, and Africa.
| Import | Export |
|---|---|
|
Trade Records
126
|
Trade Records
136
|
|
Suppliers
-
|
Buyers
-
|
|
Latest Import Date
2026-06
|
Latest Export Date
2026-06
|
According to Topease's global trade data, GEMABIOTECH S A exports products to verified importers across global markets.
Its export activity is associated with HS-code categories such as:
As an importer, GEMABIOTECH S A sources products from verified exporters across multiple regions.
Its import activity spans HS-code categories including:
Explore GEMABIOTECH S A's import activity, including trade volumes, top suppliers, sourcing countries, and key product categories. These insights allow exporters and potential suppliers to understand its global supply chains, track procurement trends, and identify new business opportunities.
Gain insights into GEMABIOTECH S A's export activities, including shipment volumes, key buyers, destination countries, and product categories. Understand global demand patterns, track sales reach, and spot opportunities to connect with potential buyers.
Access GEMABIOTECH S A's key professional contacts for B2B outreach purposes. View verified phone numbers, emails, and LinkedIn profiles to facilitate efficient business communication.
Disclaimer: Data is compiled from public and third-party sources and may not be complete or fully accurate. This information is provided for business intelligence purposes only and should not be used for legal, financial, or compliance decisions.